Non-Invasive Cardiology Devices Market Size, Share, and Industry Analysis, By Type (Electrocardiogram {Resting ECG Devices, Holter Monitors, Event Monitors, and Others}, Mobile Cardiac Telemetry (MCT), Smart Wearables, and Others), By Application (Cardiac Arrhythmia, Bradycardia, Tachycardia, and Others), By End User (Hospitals & ASCs, Specialty Clinics, Homecare Settings, and Others), and Regional Forecast, 2025-2032

Non-invasive cardiology devices are a part of preoperative practice, primarily used to achieve fluid optimization and guide the use of inotropic and vasoactive drugs for patients undergoing major surgery. These devices are mainly used to measure the cardiac output, stroke volume, and central venous pressure to evaluate the volume status of the patients. The measurement helps in proper clinician decision-making regarding fluid replacement therapies.

The increasing prevalence of cardiovascular diseases has accelerated the need for early diagnosis and treatment of cardiovascular disorders. Therefore, surgeons constantly use cardiovascular monitoring devices to monitor patient’s health status and offer the appropriate treatment options. These monitoring devices are widely used to assess the patient’s risk of developing heart problems by identifying potential signs and symptoms at an early stage, diagnosing a wide range of cardiovascular ailments by visualizing the various heart structures, and assessing heart function. Therefore, these monitoring devices' potential benefits are increasing their adoption among the population, further contributing to market growth.

Furthermore, several technological advancements in cardiac monitoring devices have enabled easy access to diagnosing cardiac malfunctions in patients. In addition, the increasing demand for smarter & wearable devices and increasing awareness regarding their need amongst patients is likely to boost the demand in the coming years. Handheld ECG devices such as KardiaMobile offer a 30-second single-lead ECG, which wirelessly transmits the ECG to a connected smartphone. Thus, constant technological advancements by the market players in the field of cardiac monitoring will contribute to market growth in the coming years.

The COVID-19 pandemic had a negative impact on the market as governments in several countries across the globe imposed several restrictions, such as the temporary halt for all elective surgeries, which subsequently declined patient visits during the pandemic. This led to a decline in the growth of the market. However, in 2021, after the subsequent lifting of the restrictions associated with the COVID-19 pandemic, the market growth returned to the pre-pandemic levels.

Segmentation

Key Insights

The report covers the following key insights:

• Overview: Technological Advancements in Non-Invasive Cardiology Devices
• New Product Launches, By Key Players
• Prevalence of Key Diseases, By Key Countries, 2023
• Key Industry Developments (Mergers, Acquisitions, and Partnerships)
• Impact of COVID-19 on the Market

Analysis by Type

By type, the market is divided into electrocardiogram, mobile cardiac telemetry (MCT), smart wearables, and others. The electrocardiogram segment held a significant proportion of the global market in 2023 owing to the growing prevalence of cardiovascular diseases amongst the population, which is leading to a growing patient preference for better treatment options, such as advanced and innovative devices.

• For instance, according to an article published in the U.S. Centers for Disease Control and Prevention in October 2023, approximately 1 in 20 adults age 20 and older had coronary artery disease (CAD) in the U.S. in 2021.

Moreover, the constant technological advancements by key market players in the field of ECG, such as the integration of advanced software and AI, have boosted the adoption of AI-enabled ECG as it provides results with maximized credibility and established clinical utility. Thus, the potential benefits offered by these technologies have increased their adoption among patients, further contributing to segmental growth.

Furthermore, the smart wearables segment is projected to witness the fastest growth in the coming years owing to the growing number of health-conscious population coupled with the increasing awareness among the population regarding the potential application of these devices. According to an article published by the NCBI in May 2023, wearable electrocardiograph devices (WEDs) have shown significant potential to enhance atrial fibrillation (AF) detection rate in primary care. Thus, the shifting preference of people toward advanced technologies is further contributing to segmental growth.

Regional Analysis

To gain extensive insights into the market, Download for Customization

The global market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the market in 2023, owing to the growing number of cases of cardiovascular diseases coupled with the increasing number of health-conscious population in the U.S. Individuals are actively shifting toward the adoption of advanced technologies to keep a proper check on their health, which is one of the factors which is contributing to the market growth. In addition, key market players in the region are significantly investing in research and development activities to launch new products into the market to meet the growing needs of patients. Thus, these factors contribute to market growth.

• In January 2022, Medically Home received USD 110.0 million in funding from investors, including Global Medical Response (GMR), Baxter International Inc.,  and Cardinal Health, which aims to advance hospital-level patient care at home by expanding its unique care model by introducing innovation in digital health and monitoring technologies.
• In May 2024, Biosense Webster, Inc., launched a new version of the CARTO 3 Electro-Anatomical Mapping System, which increases reproducibility, efficiency, and accuracy in the electro-anatomical maps, wherein electrophysiologists can use it in catheter ablation procedures. Thus, constant advancements in this field are further contributing to regional growth.

Asia Pacific is projected to witness the fastest growth rate in the coming years owing to the increasing healthcare infrastructure coupled with growing government support toward the authorization and approval of new products into the market.

Key Players Covered

The report includes the profiles of key players such as Baxter, Biobeat, General Electric Company, Koninklijke Philips N.V., and Abbott.

Key Industry Developments

• In August 2023, Acorai received the U.S. FDA authorization for Acorai's Heart Monitor, a device for the non-invasive estimation of systolic pulmonary artery pressure (sPAP), diastolic pulmonary artery pressure (dPAP), and mean pulmonary artery pressure (mPAP) in patients with Stage C Heart Failure.
• In January 2022, Sensydia received U.S. FDA authorization for its Cardiac Performance System (CPSTM). The FDA will work collaboratively with the company to accelerate the development of the cardiac performance system.
• In November 2021, Apollo Hospitals announced the launch of an “AI-powered Cardiovascular Disease Risk tool,” enabling healthcare providers to predict the risk of cardiac disease in patients and initiate early intervention.